Signals, Powered By EquityPandit
Lupin, the drug firm has received the approval from India’s Central Drugs Standard Control Organisation (CDSCO) for Bepotastine tablets that are used in treating patients suffering from allergic symptoms.
Lupin has said that it is going to commence promoting the product in the country shortly.
Lupin has said that “Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from allergies symptoms.”
It added that “It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepostatine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries.”
